Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 288

1.

Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection.

Cardin RD, Bravo FJ, Pullum DA, Orlinger K, Watson EM, Aspoeck A, Fuhrmann G, Guirakhoo F, Monath T, Bernstein DI.

Vaccine. 2016 Apr 12;34(17):1993-9. doi: 10.1016/j.vaccine.2016.03.005. Epub 2016 Mar 10.

PMID:
26973071
2.

Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.

Swanson EC, Gillis P, Hernandez-Alvarado N, Fernández-Alarcón C, Schmit M, Zabeli JC, Wussow F, Diamond DJ, Schleiss MR.

Vaccine. 2015 Jul 31;33(32):4013-8. doi: 10.1016/j.vaccine.2015.06.019. Epub 2015 Jun 13.

3.

Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.

Schleiss MR, Berka U, Watson E, Aistleithner M, Kiefmann B, Mangeat B, Swanson EC, Gillis PA, Hernandez-Alvarado N, Fernández-Alarcón C, Zabeli JC, Pinschewer DD, Lilja AE, Schwendinger M, Guirakhoo F, Monath TP, Orlinger KK.

Clin Vaccine Immunol. 2017 Jan 5;24(1). pii: e00300-16. doi: 10.1128/CVI.00300-16. Print 2017 Jan.

4.
5.

Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model.

Schleiss MR, Choi KY, Anderson J, Mash JG, Wettendorff M, Mossman S, Van Damme M.

Vaccine. 2014 May 13;32(23):2756-62. doi: 10.1016/j.vaccine.2013.07.010. Epub 2013 Jul 16.

6.

A Novel Non-Replication-Competent Cytomegalovirus Capsid Mutant Vaccine Strategy Is Effective in Reducing Congenital Infection.

Choi KY, Root M, McGregor A.

J Virol. 2016 Aug 12;90(17):7902-19. doi: 10.1128/JVI.00283-16. Print 2016 Sep 1.

7.

Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine.

Schleiss MR, Bourne N, Stroup G, Bravo FJ, Jensen NJ, Bernstein DI.

J Infect Dis. 2004 Apr 15;189(8):1374-81. Epub 2004 Apr 1.

PMID:
15073673
8.

Vaccination with a Live Attenuated Cytomegalovirus Devoid of a Protein Kinase R Inhibitory Gene Results in Reduced Maternal Viremia and Improved Pregnancy Outcome in a Guinea Pig Congenital Infection Model.

Schleiss MR, Bierle CJ, Swanson EC, McVoy MA, Wang JB, Al-Mahdi Z, Geballe AP.

J Virol. 2015 Oct;89(19):9727-38. doi: 10.1128/JVI.01419-15. Epub 2015 Jul 15.

9.

Immunogenicity evaluation of DNA vaccines that target guinea pig cytomegalovirus proteins glycoprotein B and UL83.

Schleiss MR, Bourne N, Jensen NJ, Bravo F, Bernstein DI.

Viral Immunol. 2000;13(2):155-67.

PMID:
10892996
10.

Effects of immunization of pregnant guinea pigs with guinea pig cytomegalovirus glycoprotein B on viral spread in the placenta.

Hashimoto K, Yamada S, Katano H, Fukuchi S, Sato Y, Kato M, Yamaguchi T, Moriishi K, Inoue N.

Vaccine. 2013 Jun 28;31(31):3199-205. doi: 10.1016/j.vaccine.2013.04.078. Epub 2013 May 15.

PMID:
23684839
11.

Protection against congenital cytomegalovirus (CMV) disease, conferred by a replication-disabled, bacterial artificial chromosome (BAC)-based DNA vaccine.

Schleiss MR, Stroup G, Pogorzelski K, McGregor A.

Vaccine. 2006 Sep 11;24(37-39):6175-86. Epub 2006 Jul 18.

PMID:
16879902
12.

Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection.

Schleiss MR, Lacayo JC, Belkaid Y, McGregor A, Stroup G, Rayner J, Alterson K, Chulay JD, Smith JF.

J Infect Dis. 2007 Mar 15;195(6):789-98. Epub 2007 Feb 6.

PMID:
17299708
13.

An attenuated cytomegalovirus vaccine with a deletion of a viral chemokine gene is protective against congenital CMV transmission in a guinea pig model.

Leviton MP, Lacayo JC, Choi KY, Hernandez-Alvarado N, Wey A, Schleiss MR.

Clin Dev Immunol. 2013;2013:906948. doi: 10.1155/2013/906948. Epub 2013 Aug 20.

14.

Congenital Cytomegalovirus: a "Now" Problem-No Really, Now.

Bernstein DI.

Clin Vaccine Immunol. 2017 Jan 5;24(1). pii: e00491-16. doi: 10.1128/CVI.00491-16. Print 2017 Jan.

15.

Comparison of vaccine strategies against congenital CMV infection in the guinea pig model.

Schleiss MR.

J Clin Virol. 2008 Mar;41(3):224-30. Epub 2007 Dec 3. Review.

PMID:
18060834
17.

Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.

Chiuppesi F, Nguyen J, Park S, Contreras H, Kha M, Meng Z, Kaltcheva T, Iniguez A, Martinez J, La Rosa C, Wussow F, Diamond DJ.

J Virol. 2018 Sep 12;92(19). pii: e01012-18. doi: 10.1128/JVI.01012-18. Print 2018 Oct 1.

18.
19.

Effect of maternal treatment with cyclic HPMPC in the guinea pig model of congenital cytomegalovirus infection.

Bravo FJ, Cardin RD, Bernstein DI.

J Infect Dis. 2006 Feb 15;193(4):591-7. Epub 2006 Jan 13.

PMID:
16425139
20.

The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.

Lilja AE, Mason PW.

Vaccine. 2012 Nov 19;30(49):6980-90. doi: 10.1016/j.vaccine.2012.09.056. Epub 2012 Oct 3. Review.

PMID:
23041121

Supplemental Content

Support Center